S. Romito

1.5k total citations · 1 hit paper
23 papers, 871 citations indexed

About

S. Romito is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, S. Romito has authored 23 papers receiving a total of 871 indexed citations (citations by other indexed papers that have themselves been cited), including 16 papers in Oncology, 10 papers in Pulmonary and Respiratory Medicine and 3 papers in Surgery. Recurrent topics in S. Romito's work include Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Gastric Cancer Management and Outcomes (5 papers). S. Romito is often cited by papers focused on Cancer Treatment and Pharmacology (8 papers), Colorectal Cancer Treatments and Studies (7 papers) and Gastric Cancer Management and Outcomes (5 papers). S. Romito collaborates with scholars based in Italy, United States and Czechia. S. Romito's co-authors include Evaristo Maiello, Vittorio Gebbia, Francesco Giuliani, Giuseppe Colucci, Luigi Manzione, Giacomo Cartenì, Ernesto Durini, Nicola Borsellino, G Paoletti and Giuseppe Pezzella and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Annals of Oncology.

In The Last Decade

S. Romito

23 papers receiving 833 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell’Italia Meridionale

2005 586 citations Giuseppe Colucci, Vittorio Gebbia et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Romito Italy	12	645	330	223	153	121	23	871
G Paoletti Italy	13	781 1.2×	352 1.1×	232 1.0×	152 1.0×	132 1.1×	29	977
Jian-Ming Xu China	12	578 0.9×	341 1.0×	176 0.8×	98 0.6×	167 1.4×	15	818
Krzysztof Jeziorski Poland	11	474 0.7×	259 0.8×	137 0.6×	174 1.1×	102 0.8×	28	820
Jason S. Starr United States	14	643 1.0×	224 0.7×	121 0.5×	272 1.8×	143 1.2×	79	1.0k
Frédérique Maindrault‐Gœbel France	8	757 1.2×	299 0.9×	167 0.7×	147 1.0×	141 1.2×	14	966
Seung‐Hoon Beom South Korea	17	459 0.7×	361 1.1×	77 0.3×	230 1.5×	150 1.2×	69	901
Mehmet Akce United States	16	847 1.3×	255 0.8×	155 0.7×	275 1.8×	187 1.5×	115	1.2k
G. Gruia United States	7	1.1k 1.6×	332 1.0×	374 1.7×	268 1.8×	204 1.7×	12	1.2k
Adina Croitoru Romania	15	307 0.5×	125 0.4×	256 1.1×	171 1.1×	128 1.1×	74	779
Yvonne Lassere United States	14	761 1.2×	320 1.0×	69 0.3×	205 1.3×	146 1.2×	20	887

Countries citing papers authored by S. Romito

Since Specialization

Citations

This map shows the geographic impact of S. Romito's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Romito with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Romito more than expected).

Fields of papers citing papers by S. Romito

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Romito. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Romito. The network helps show where S. Romito may publish in the future.

Co-authorship network of co-authors of S. Romito

This figure shows the co-authorship network connecting the top 25 collaborators of S. Romito. A scholar is included among the top collaborators of S. Romito based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Romito. S. Romito is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Orlando, Laura, Vito Lorusso, Francesco Giotta, et al.. (2020). Metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with trastuzumab (HEX) as first line therapy of HER-2 positive advanced breast cancer: A phase II trial of the Gruppo Oncologico Italia Meridionale (GOIM). The Breast. 53. 18–22. 15 indexed citations

Lorusso, Vito, Francesco Giotta, Roberto Bordonaro, et al.. (2014). Non-pegylated liposome-encapsulated doxorubicin citrate plus cyclophosphamide or vinorelbine in metastatic breast cancer not previously treated with chemotherapy: A multicenter phase III study. International Journal of Oncology. 45(5). 2137–2142. 14 indexed citations

Improta, Giuseppina, Angela Zupa, Emanuela Stampone, et al.. (2014). Pyrosequencing Evaluation of Low-Frequency KRAS Mutant Alleles for EGF Receptor Therapy Selection in Metastatic Colorectal Carcinoma. Future Oncology. 10(5). 713–723. 14 indexed citations

Bisceglie, M. Di, et al.. (2012). Una nuova opzione terapeutica nel carcinoma prostatico ormonorefrattario. Recenti Progressi in Medicina. 103(2). 74–8. 4 indexed citations

Bisceglie, M. Di, et al.. (2011). Un caso di schwannoma retroperitoneale. Recenti Progressi in Medicina. 102(7). 307–9. 2 indexed citations

Romito, S., et al.. (2009). Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2. International Journal of Hematology. 90(1). 81–86. 2 indexed citations

Giuliani, Francesco, S. Romito, Evaristo Maiello, et al.. (2008). Epirubicin, taxotere and fluorouracil modulated by folinic acid in the treatment of advanced gastric cancer: A phase II study of the Gruppo Oncologico dell’ Italia Meridionale (GOIM). European Journal of Cancer Supplements. 6(14). 107–112. 1 indexed citations

Giuliani, Francesco, Ferdinando De Vita, Evaristo Maiello, et al.. (2008). Folfiri versus xeliri in untreated advanced colorectal cancer: A phase II randomised trial of the Gruppo Oncologico dell’ Italia Meridionale (prot. GOIM 2405). European Journal of Cancer Supplements. 6(14). 120–121. 2 indexed citations

Vita, Ferdinando De, Francesco Giuliani, Michele Orditura, et al.. (2007). Adjuvant chemotherapy with epirubicin, leucovorin, 5-fluorouracil and etoposide regimen in resected gastric cancer patients: a randomized phase III trial by the Gruppo Oncologico Italia Meridionale (GOIM 9602 Study). Annals of Oncology. 18(8). 1354–1358. 75 indexed citations

10.

Maiello, Evaristo, Francesco Giuliani, Vittorio Gebbia, et al.. (2006). FOLFIRI with or without celecoxib in advanced colorectal cancer: a randomized phase II study of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology. 17. vii55–vii59. 23 indexed citations

11.

Lorusso, Vito, Domenico Galetta, Francesco Giotta, et al.. (2006). Topotecan in the treatment of brain metastases. A phase II study of GOIM (Gruppo Oncologico dell'Italia Meridionale).. PubMed. 26(3B). 2259–63. 19 indexed citations

12.

Vita, Ferdinando De, Francesco Giuliani, Vittorio Gebbia, et al.. (2006). Surgery plus ELFE (epirubicin, leucovorin, 5-fluorouracil and etoposide) vs surgery alone in radically resected gastric cancer (GC): Final results of a randomised phase III trial by the Gruppo Oncologico dell’ Italia Meridionale (GOIM). Journal of Clinical Oncology. 24(18_suppl). 4014–4014. 1 indexed citations

13.

Maiello, Evaristo, Vittorio Gebbia, Francesco Giuliani, et al.. (2005). FOLFIRI regimen in advanced colorectal cancer: the experience of the Gruppo Oncologico dell'Italia Meridionale (GOIM). Annals of Oncology. 16. iv56–iv60. 16 indexed citations

14.

Maiello, Evaristo, Francesco Giuliani, S. Romito, et al.. (2005). Phase II randomized study of FOLFIRI vs FOLFIRI + celecoxib in first line treatment of advanced colorectal cancer (ACRC). Journal of Clinical Oncology. 23(16_suppl). 3656–3656. 1 indexed citations

15.

Galetta, Domenico, Vittorio Gebbia, Francesco Giotta, et al.. (2002). Gemcitabine and docetaxel every 2 weeks in advanced non-small cell lung cancer: a phase II study of the Gruppo Oncologico Italia Meridionale. Lung Cancer. 38(1). 79–84. 16 indexed citations

16.

Colucci, Giuseppe, Francesco Giotta, Vittorio Gebbia, et al.. (1997). Dose intensification of mitoxantrone in combination with levofolinic acid, fluorouracil, cyclophosphamide and granulocyte colony stimulating factor support in advanced untreated breast cancer patients. A multicentric phase II study of the Southern Italy Oncology Group. Anti-Cancer Drugs. 8(3). 257–264. 1 indexed citations

17.

Colucci, Giuseppe, S. Romito, Vittorio Gebbia, et al.. (1995). Laevofolinic acid, 5-fluorouracil, cyclophosphamide and escalating doses of epirubicin with granulocyte colony-stimulating factor support in locally advanced and/or metastatic breast carcinoma: a phase I-II study of the Southern Italy Oncology Group (GOIM). British Journal of Cancer. 72(5). 1245–1250. 5 indexed citations

18.

Lena, Mario De, et al.. (1989). Comparison of CHOP-B vs CEOP-B in ‘poor prognosis’ non-Hodgkin’s lymphomas. A randomized trial. Medical Oncology and Tumor Pharmacotherapy. 6(2). 163–169. 17 indexed citations

19.

Lena, Mario De, et al.. (1988). 4-Demethoxydaunorubicin Administered Orally in Advanced Breast Cancer. Tumori Journal. 74(1). 65–70. 5 indexed citations

20.

Lena, M. De, Vito Lorusso, & S. Romito. (1986). "Cisplatin plus etoposide as second-line treatment in advanced ovarian carcinoma".. PubMed. 70(7). 790–5. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact